Abstract
Alzheimer’s and Parkinson’s diseases are prevalent neurodegenerative disorders worldwide, which are essentially related to aging. Within the remarkable era of nanomedicine, nowadays several delivery systems have been suggested to improve the treatment of these disorders, namely, liposomes, micelles, nanoparticles (polymeric, lipid, metallic and inorganic), exosomes, dendrimers and fullerenes. The advantage that has been claimed to these delivery systems is that they facilitate the passage of drugs through the blood brain barrier (BBB), enabling targeting before body degradation, and increasing therapeutic efficacy, comparied to conventional pharmaceutical dosage forms.
This review article provides a state of the art regarding the drug delivery systems that have been studied for the treatment of Alzheimer’s and Parkinson’s diseases. It begins with a brief description of the central nervous system (CNS) and the mechanisms involved in the development of these diseases. Later, some examples of drugs used in the treatment of these neurodegenerative diseases are presented, which are currently available in conventional pharmaceutical dosage forms, and in new drug delivery systems that are under development.
Keywords: Alzheimer's disease, Parkinson’s disease, Liposomes, Micelles, Nanoparticles, Exosomes, Dendrimers, Fullerenes.
Current Medicinal Chemistry
Title:Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Volume: 23 Issue: 31
Author(s): S. Cunha, M. H. Amaral, J. M. Sousa Lobo and A. C. Silva
Affiliation:
Keywords: Alzheimer's disease, Parkinson’s disease, Liposomes, Micelles, Nanoparticles, Exosomes, Dendrimers, Fullerenes.
Abstract: Alzheimer’s and Parkinson’s diseases are prevalent neurodegenerative disorders worldwide, which are essentially related to aging. Within the remarkable era of nanomedicine, nowadays several delivery systems have been suggested to improve the treatment of these disorders, namely, liposomes, micelles, nanoparticles (polymeric, lipid, metallic and inorganic), exosomes, dendrimers and fullerenes. The advantage that has been claimed to these delivery systems is that they facilitate the passage of drugs through the blood brain barrier (BBB), enabling targeting before body degradation, and increasing therapeutic efficacy, comparied to conventional pharmaceutical dosage forms.
This review article provides a state of the art regarding the drug delivery systems that have been studied for the treatment of Alzheimer’s and Parkinson’s diseases. It begins with a brief description of the central nervous system (CNS) and the mechanisms involved in the development of these diseases. Later, some examples of drugs used in the treatment of these neurodegenerative diseases are presented, which are currently available in conventional pharmaceutical dosage forms, and in new drug delivery systems that are under development.
Export Options
About this article
Cite this article as:
Cunha S., Amaral H. M., Lobo M. Sousa J. and Silva C. A., Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems, Current Medicinal Chemistry 2016; 23 (31) . https://dx.doi.org/10.2174/0929867323666160824162401
DOI https://dx.doi.org/10.2174/0929867323666160824162401 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibody Recognition of Fluorinated Haptens and Antigens
Current Topics in Medicinal Chemistry Current Status and Future of Antifungal Therapy for Systemic Mycoses
Recent Patents on Anti-Infective Drug Discovery The Application of Angiotensin Converting Enzyme Inhibitors in Heart Surgery
Letters in Drug Design & Discovery Severe Preeclampsia
Current Women`s Health Reviews Natural Anticoagulant Proteins in the Regulation of Autoimmunity: Potential Role of Protein S
Current Pharmaceutical Design The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Pharmaceutical Design Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry The Phospholipase A2 Homologues of Snake Venoms: Biological Activities and Their Possible Adaptive Roles
Protein & Peptide Letters Routine use of Corticosteroids to Prevent Inflammation Response in Cardiac Surgery
Recent Patents on Cardiovascular Drug Discovery Low Doses of G-CSF Prevent Cerebral Infarction and Maintain Muscle Strength in an Experimental Model of Global Ischemic Stroke
Current Pharmaceutical Biotechnology Stage A: Can Heart Failure Be Prevented?
Current Cardiology Reviews Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design Drug Therapy in Schizophrenia
Current Pharmaceutical Design Comparing the Molecular Pharmacology of CGRP and Adrenomedullin
Current Protein & Peptide Science Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Recent Advances in Exercise Testing
Current Cardiology Reviews Diabetes Mellitus during the Pandemic Covid-19: Prevalence, Pathophysiology, Mechanism, and Management: An updated overview
Current Diabetes Reviews Antenatal Glucocorticoids Supplementation and Central Nervous System Development
Current Drug Metabolism New Drugs for Epidural Analgesia
Current Drug Targets